View Older Stories View More Recent Stories

May 9, 2023 07:00AM RedHill Publishes New Talicia® Data on Generic Non-Bioequivalence in AP&T and Presents New Dosing Data at Digestive Disease Week
May 1, 2023 07:04AM RedHill Biopharma's (RDHL) RHB-102 and Opaganib Granted New Patents in Oncology Setting
May 1, 2023 07:00AM RedHill's RHB-102 (BEKINDA®) and Opaganib Granted New Patents in Oncology Setting
Apr 28, 2023 07:00AM RedHill Biopharma Announces Q4/22 & Full-Year 2022 Results and Operational Highlights
Apr 11, 2023 07:00AM RedHill Biopharma Regains Compliance with Nasdaq Minimum Bid Price Requirement
Apr 3, 2023 01:26PM RedHill Biopharma Announces Closing of $6 Million Registered Direct Offering
Mar 30, 2023 08:02AM RedHill Biopharma (RDHL) Announces $6 Million Registered Direct Offering of ADSs and Warrants
Mar 30, 2023 08:00AM RedHill Biopharma Announces $6 Million Registered Direct Offering
Mar 21, 2023 07:00AM RedHill Initiates First Community-Setting Warranty Program to Refund Talicia Non-Responders
Mar 17, 2023 05:49AM RedHill Biopharma (RDHL) to Implement ADS Ratio Change to 1:400
Mar 16, 2023 06:15PM RedHill Biopharma Announces Plan to Implement ADS Ratio Change
Mar 8, 2023 07:05PM RedHill Biopharma Announces Definitive Agreement for Up To $6 Million Private Placement with a Single Investor
Feb 28, 2023 08:02AM RedHill Biopharma (RDHL) Announces RDHL Opaganib Selected by NIH RNCP For Development
Feb 28, 2023 08:01AM RedHill Biopharma Ltd Announces RDHL Opaganib Selected by NIH RNCP For Development
Feb 28, 2023 07:00AM RedHill's Opaganib Selected by the NIH Radiation and Nuclear Countermeasures Program
Feb 16, 2023 08:04AM RedHill Biopharma (RDHL) Announces RedHill's RHB-102 Positive MHRA Meeting & MAA Plan
Feb 16, 2023 08:01AM RedHill Biopharma Ltd Announces RedHill's RHB-102 Positive MHRA Meeting & MAA Plan
Feb 16, 2023 08:00AM RedHill Announces Positive MHRA Meeting and Planned UK Marketing Authorisation Application of RHB-102 (BEKINDA®) for Oncology Support
Feb 15, 2023 07:01AM RedHill Biopharma (RDHL) Announces Positive FDA Meeting Regarding Opaganib for Acute Nuclear Radiation Syndrome
Feb 15, 2023 07:00AM RedHill Biopharma Announces Positive FDA Meeting Regarding Opaganib for Acute Nuclear Radiation Syndrome
Feb 6, 2023 07:00AM RedHill Biopharma and HealthCare Royalty Agree to Extinguish All RedHill's Debt Obligations in Exchange for Movantik®
Jan 26, 2023 07:00AM RedHill Receives USPTO Notice of Allowance for a Patent Covering Phase 3-stage RHB-204 for the Treatment of NTM Disease
Jan 3, 2023 07:01AM RedHill Biopharma (RDHL) Reports Publication of Positive Phase 2 Data for RHB-107
Jan 3, 2023 07:00AM RedHill Announces Publication of Positive Phase 2 Study Results with Once-Daily Oral RHB-107 in Non-Hospitalized COVID-19
Dec 6, 2022 01:36PM RedHill Biopharma Closes $8.0 Million Underwritten Public Offering
Dec 5, 2022 07:00AM RedHill's Aemcolo® Granted FDA QIDP 5-Year Exclusivity Extension
Dec 2, 2022 09:01AM RedHill Biopharma (RDHL) Prices $8.0 Million Underwritten Public Offering
Dec 2, 2022 09:00AM RedHill Biopharma Prices $8.0 Million Underwritten Public Offering
Dec 1, 2022 04:01PM RedHill Biopharma (RDHL) Announces Proposed Public Offering of ADSs
Dec 1, 2022 04:01PM RedHill Biopharma Announces Proposed Public Offering
Nov 29, 2022 08:00AM RedHill Biopharma Announces Q3/22 Results and Operational Highlights
Nov 17, 2022 08:32AM RedHill Biopharma (RDHL) Reports Positive New Data with Opaganib for Nuclear Radiation Injury
Nov 17, 2022 08:30AM RedHill Biopharma Announces Positive New Data with Opaganib for Nuclear Radiation Injury
Nov 14, 2022 07:00AM RedHill Accelerates Opaganib's Nuclear Radiation Protection Program - Positive Data Published
Nov 14, 2022 06:04AM RedHill Biopharma (RDHL) Reaches Agreement with HCR to Extinguish All Debt Obligations in Exchange for Movantik
Nov 14, 2022 06:00AM RedHill Biopharma Reaches Agreement in Principle with HCR to Extinguish All Debt Obligations in Exchange for Movantik®
Nov 7, 2022 09:50AM RedHill Biopharma (RDHL) Provides H1'22 Highlights and Q3 Estimates
Nov 7, 2022 09:49AM RedHill Biopharma Provides H1/22 Highlights and Q3/22 Estimates
Nov 4, 2022 07:02AM RedHill Biopharma (RDHL) Presents New Talicia Data Analyses
Nov 4, 2022 07:00AM RedHill Presents New Talicia® Data Analyses at Obesity Week 2022
Oct 26, 2022 07:00AM RedHill Presents New Talicia® and Movantik® Data Analyses at ACG 2022
Oct 19, 2022 07:00AM RedHill's Oral Broad-Acting Antiviral, Opaganib, Granted New COVID-19 Treatment Patent
Oct 18, 2022 07:00AM RedHill Biopharma Announces Receipt of Nasdaq Notification Regarding Minimum Bid Price Deficiency
Oct 3, 2022 07:00AM RedHill's Oral Broad-Acting Antivirals, Opaganib and RHB-107, Inhibit Dominant Omicron Sub-Variant BA.5
Aug 17, 2022 08:01AM RedHill Biopharma (RDHL) Granted EU Orphan Drug Designation for RHB-204
Aug 17, 2022 08:00AM RedHill Biopharma Announces EU Orphan Drug Designation for RHB-204 for NTM Infections
Jul 12, 2022 08:00AM RedHill Announces New H. pylori and COVID-19 Data Publication and Presentations at Leading Upcoming Scientific Conferences
Jun 23, 2022 07:00AM RedHill Biopharma Announces Q1/22 Highlights: On Track for Positive Cash from Operations in H2/22
Jun 17, 2022 08:30AM RedHill Biopharma to Host First Quarter 2022 Financial Results and Operational Highlights Webcast on June 23, 2022
May 25, 2022 09:15AM RedHill Presents New Talicia® Data Analyses at DDW 2022
View More Recent Stories View Older Stories